Jeff Schaffnit Shares Sanofi’s Patient Advocacy Voices Series with Caroline Kruse
Jeff Schaffnit, General Manager and Head of Rare Blood Disorders at Sanofi, shared on LinkedIn:
”Many people living with immune thrombocytopenia (ITP) face a critical hurdle: getting a proper diagnosis.
Caroline Kruse, President and CEO of the Platelet Disorder Support Association – PDSA, and other experts know this challenge well.
Despite the organization’s over 25 years of educating, supporting and advocating for the ITP community, diagnosis remains one of the most critical unmet needs for people living with ITP and other rare blood disorders.
My colleague Eric Racine, PharmD, MBA had the opportunity to speak with Caroline as part of Sanofi’s Patient Advocacy Voices series.
We stand proudly with PDSA and the ITP community in our commitment to raising awareness and supporting people living with ITP.
Watch the full conversation here.”
Stay updated with Hemostasis Today.
-
Mar 16, 2026, 07:26James Crowley, Professor of Medicine emeritus at Brown University, posted on LinkedIn:
-
Mar 15, 2026, 15:55Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 2
-
Mar 15, 2026, 14:09Abdul Mannan: A Red Eye, a Blood Clot, and Ibrutinib – The Clinical Tightrope
-
Mar 15, 2026, 14:02Denise M: Precision Hemostasis in Patient Blood Management
-
Mar 15, 2026, 13:57Abdulrahman Nasiri: D14 Bone Marrow Biopsy in AML Induction in the Era of Targeted Therapies
-
Mar 15, 2026, 13:52Valentin Ortiz-Maldonado: High-Impact Innovation in CAR-T Therapy Can Emerge From Academic Programmes
-
Mar 15, 2026, 13:45Tareq Abadl: Has Anyone Here Ever Taken an ALP Test Before?
-
Mar 14, 2026, 21:30Ayman Elbadawi: Why Does Stent Thrombosis Still Occur? Insights from the NCDR Data
-
Mar 14, 2026, 20:03Edward Adomako: Recognizing Thrombotic Thrombocytopenic Purpura as A Life-Threatening Emergency